Introduction
The present classification of renal tumors is based on cytological appearance and the cell type of origin in combination with growth pattern and genetic alterations. 8 According to this classification, papillary renal cell carcinoma is recognized as a distinct subtype of renal carcinoma, which comprises 10-15% of cases in surgical series. It is characterized by predominant papillary or tubulopapillary histol- 7, 8 There is debate concerning the relative outcome of papillary renal cell carcinoma compared to clear cell type, which could probably be resolved by adopting this recently proposed subclassification.
Cell adhesion molecules are involved in various physiological and pathological processes including cancer. Among them, CD44 molecule has received much interest as a major cell adhesion and signaling molecule involved in tumor progression. 26 It is a widely distributed cell surface glycoprotein expressed as many isoforms arising from a single gene by alternative splicing. One of them is CD44v6, a variant that has been identified as a marker of cancer progression. 13 A principal ligand for the standard form of CD44 is hyaluronan, but ligands for the variant isoforms are not as well characterized. One of the proposed ligands is osteopontin, a secreted adhesive glycoprotein, expressed by various mesenchymal and epithelial cells, and involved in a variety of physiological functions, as well as in tumorigenesis and metastasis. 23 Osteopontin contains binding sites for several receptors, including CD44 and integrin αvβ3, cell surface molecules playing a major role in mediating cell migration and adhesion. 20 An increase in osteopontin expression levels has been shown to correlate with enhanced malignancy in several in vitro and in vivo studies. 1, 5, 21, 24 High expression of both adhesion molecules, CD44 and osteopontin, has been shown to correlate with poor prognostic parameters in clear cell type of renal cell carcinoma, which is the most common type of renal cancer. 10, 18, 19, 22 However, to our knowledge, there are no reports on the expression of these two adhesion molecules in papillary renal cell carcinoma.
The current study was undertaken to investigate the expression of osteopontin and CD44 molecule in papillary renal cell carcinoma, in order to better characterize this rare type of renal cancer, and to compare the results with prognostic parameters.
Materials and methods

Tumor samples
We examined 50 consecutive nephrectomy specimens in which papillary renal cell tumors had been diagnosed during the routine pathological work from January 1989 till September 2004. Since typing and grading of renal cell carcinoma have markedly changed in the past decade, all hematoxylin-eosin-stained sections from each case were reviewed by two pathologists, followed by exclusion of 3 cases, which did not meet criteria for papillary renal cell carcinoma diagnosis according to WHO classification. 8 The tumors were classified as adenoma or carcinoma, after examination of hematoxylin-eosin-stained tissue sections, according to WHO criteria, and graded using the Fuhrman nuclear grading system. 16 Four cases were excluded on the basis of incomplete clinical data or inadequate archival material, so a total of 43 specimens were finally included in the study. Five tumors consisted of tubulopapillary structures lined by small, cuboidal cells with rounded, uniform nuclei lacking cytological atypia. Tumors were circumscribed, but not encapsulated, without stromal reaction, mitoses were absent or rare. These tumors were classified as adenomas, and the other 38 samples, exhibiting at least 75% papillary or tubulopapillary architecture, which did not meet the above mentioned criteria, were classified as papillary renal cell carcinoma. Carcinoma samples were further subdived into the type 1 (single-layered small cells with pale cytoplasm and small oval nuclei with inconspicuous nucleoli) and type 2 (pseudostratified large cells with abundant eosinophilic cytoplasm and large nuclei with prominent nucleoli), according to criteria proposed by Delahunt et al. 7 Tumor stage was defined according to the International Union Against Cancer (IUCC) 1997 tumor-node-metastasis (TNM) classification. 12 
Immunohistochemistry
For each case of papillary renal cell carcinoma, a representative slide of the tumor and the corresponding paraffin block was selected. Five-micron sections were cut on glass slides (DakoCytomation, Glostrup, Denmark), and air-dried during the night. Following deparaffinization in xylene and rehydration in alcohol, heat-induced epitope retrieval was achieved by immersing slides in 10 mM citrate buffer (pH 6.0) and boiling for 10 minutes in a pressure cooker. Slides were allowed to cool for 45 minutes, and then pre-incubated with blocking solution containing normal donkey serum (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for osteopontin staining, or normal goat serum (DakoCytomation) for CD44 staining, respectively, for 30 minutes. The staining was performed by indirect immunoperoxidase s protocol. Murine monoclonal antibodies against CD44s (clone SFF304, dilution 1:15000) and CD44v6 (clone VFF-18, dilution 1:15000) were purchased from Bender MedSystems (Vienna, Austria), and applied overnight at +4°C. For negative control, an irrelevant murine monoclonal IgG antibody was used (DakoCytomation). For positive controls, a staining of intratumoral lymphocytes for CD44s, and urothelium for v6 isoform, was used.
Osteopontin was detected by goat anti-human monoclonal antibody (clone K-20, Santa Cruz Biotechnology, dilution 1:100), followed by donkey anti-goat IgG as sec- 
Evaluation of immunohistochemistry
Immunohistochemical staining results were examined independently by two pathologists, without knowledge of the nuclear grade or other clinicopathological parameters of each individual case. Cases without any detectable staining were considered negative, as well as those with only focal positivity, found in less than 1% of tumor cells. Positive staining for CD44 molecule and osteopontin was defined as membranous or granular cytoplasmic positivity, respectively, found in more than 1% of tumor cells. Tumor growth kinetics was determined by immunohistochemical detection of Ki-67 antigen. Ki-67 antigen expression was assessed in areas with the highest density of positive cells, and expressed as Ki-67 labeling index (percentage of positive cells) by scoring 500 tumor cells at high power field. The counting was performed on image analyzer using ISSA 3.1 software (Vams, Zagreb, Croatia).
Statistical analysis
Statistical analysis was performed using Statistica 6.1 software (StatSoft, Inc., Tulsa, OK, USA). Pearson ' s χ 2 test was used to assess the significance of associations between categorical data. The mean values of continuous data, such as Ki-67 proliferation index and tumor size, were compared by Student ' s t-test. Statistical differences with p value less than 0.05 were considered significant.
Results
Clinicopathological data
The sex distribution was as follows: 4 men and 1 woman for papillary renal cell adenomas, and 30 men and 8 women for papillary renal cell carcinomas. Tumor size for papillary adenomas was 0.6±0.2 cm, while papillary carcinomas measured 6.6±3.6 cm in diameter. The Fuhrman grading distribution was as follows: 3 grade 1, 23 grade 2, 8 grade 3, and 4 grade 4 tumors. Pathological staging according to the TNM classification was pT1 in 19 casespT2 in 13 cases, and pT3 in 6 cases.
Immunohistochemical staining in normal renal tissue and papillary renal cell adenomas
In the normal renal parenchyma no staining for CD44s or v6 isoforms was observed, except for a few CD44s-and v6-positive tubules, usually in the close vicinity to the tumor tissue. Stromal cells, like lymphocytes and macrophages were also positive for CD44s. Staining was of membranous type, in contrast to staining pattern of osteopontin, which was granular and cytoplasmic. The expression of osteopontin was seen in distal tubular epithelial cells, and was usually most prominent along the luminal side of the cell. Calcifications and stromal cells like macrophages and plasma cells were also positive (Figure 1d ). Papillary renal adenomas were negative for CD44s and CD44v6 isoforms, except for one case in which a focal staining of a few tumor cells with anti-CD44s was observed. Staining for osteopontin protein was present in all tumors, although it was generally of lower intensity, and in smaller proportion of tumor cells, comparing to papillary renal cell carcinoma.
Immunohistochemical staining in papillary renal cell carcinomas
Sixteen samples were negative for CD44s (42%), while upregulation of CD44s molecule was found in 22 cases (58%) ( Table 1) . Staining pattern was heterogeneous, ranging from weak positivity in part of the tumor to strong and diffuse staining of almost all tumor cells (Figure 1b) . It was always of membranous type, and usually present along the basolateral surface of the cell. CD44v6 was expressed in 12 (32%) tumors, with 8 tumors of type 1 and 4 tumors of type 2 morphology (Figure 1c) .
All papillary renal cell carcinomas, except one, were positive for osteopontin (Figure 1e, f) . Staining was present in the cytoplasm in the form of granules of various sizes and staining intensity. The granules were distributed either evenly, or were showing perinuclear or perimembranous distribution. The pattern of staining varied between samples and ranged from staining of small number of tumor cells with low intensity to strong and diffuse positivity throughout the tumor. The proportion of positive cells varied with predominant expression in more than 50% of tumor cells.
Association between CD44 expression and clinicopathological characteristics
The expression of CD44 molecule was compared to usual prognostic parameters in renal cell carcinomas such as tumor size, Fuhrman nuclear grade, pathological stage, and Ki-67 proliferation index (Table 1) . We could find statistically significant association of CD44s expression only with pathological stage (p=0.026), with higher incidence of CD44s positivity in tumors confined within kidneys (i.e., pT1 or pT2), compared to those invading beyond the kidneys (i.e., pT3 or pT4). Other clinicopathological variables were not associated with the expression of the CD44 molecule, neither CD44s (Table 1) , nor CD44v6 (data not shown).
Clinicopathological characteristics of papillary renal cell carcinomas in relation to histological type
The results of clinicopathological parameters in relation to 2 morphological types of papillary renal cell carcinoma are shown in Table 2 . Mean diameter of type 1 carcinomas was smaller then that of type 2 carcinomas (6.2±3.3 cm versus 7.7±4.4 cm), but the difference was not significant (p=0.254). There was a significant difference in the distribution of nuclear grades and pathological stages between type 1 and type 2 papillary renal cell carcinomas (p<0.001 and p=0.026, respectively). The majority of type 1 papillary renal cell carcinomas were of lower nuclear grade and localized to the kidney at the time of diagnosis, whereas type 2 tumors were mostly of higher nuclear grade and frequently presented with locally invasive disease. Analysis of tumor growth fraction showed Ki-67 index to be significantly higher for type 2 (10.7±8.4) compared to type 1 tumors (3.3±2.8) (p<0.001).
Discussion
In the present study we demonstrated the upregulation of CD44s and v6 isoforms in papillary renal cell carcinomas, in opposite to adenomas, and the constitutive expression of osteopontin in both types of papillary renal cell tumors. Numerous investigators reported the prognostic significance of CD44s overexpression in clear cell type of renal cell carcinoma, which is the most common type of renal cancer. 10, 19, 22 However, there are limited data regarding the expression of CD44 molecule in papillary renal cell carcinoma, and as a rule, the number of cases is too small to achieve relevant conclusion. In addition, papillary carcinomas were always considered as a group, without data for particular tumor type proposed by Delahunt et al. 7 Our results contrasted with that of Heider et al. who found papillary renal cell carcinoma almost completely devoid of CD44 expression, including the CD44s isoform. 15 In the study of Terpe et al. on 7 papillary renal cell carcinomas, CD44s, v6 and v9 isoforms were detected only in nuclear grade 2 tumors, while all grade 1 cases were negative. 25 In our study, the expression of CD44s and v6 isoforms was not associated with nuclear grade, neither considering all tumors as a group, nor for particular types. In contrast to results obtained on clear cell carcinomas, 22 the expression of CD44s and v6 was associated with lower pathological stage. Furthermore, in type 2, which often presents in higher pathological stages, all CD44s-positive cases presented in low pathological stages. Our findings corroborate those described by Gilcrease et al., 10 who also found increased expression of CD44s and v6 in papillary renal cell carcinoma versus clear cell carcinoma, and in low versus high tumor stages, although the number of cases was to small to achieve statistical significance. It seems that overexpression of CD44s and v6 isoforms in papillary renal cell carcinoma, although present in higher proportion of cases compared to clear cell carcinoma, does not provide any useful prognostic information. Growing evidence supports a role for osteopontin as a potential prognostic factor in various human cancers. Osteopontin RNA and protein have been found to be overexpressed in a number of human tumor types, relative to normal tissue, and this overexpression has been associated with progression of the disease and patients' survival. 1, 5, 19, 21, 24 However, there are no reports on osteopontin expression in papillary renal cell carcinoma, except for reporting of one positive well-differentiated papillary renal cell carcinoma case in the study of Brown et al. 4 Coppola et al. described a correlation between the level of osteopontin expression and tumor stage in renal cell carcinoma, but the type of renal cancer was not mentioned. 5 We have recently shown the overexpression of osteopontin in 45.5% of clear cell carcinoma samples, which was associated with well-known predictors of poor outcome: higher nuclear grade, higher pathological stage and high tumor growth kinetics. 18 All grade 1 clear cell carcinomas were negative for osteopontin, while the number of positive samples increased with transformation to higher nuclear grade. In the present study on the papillary type of renal cancer, the expression of osteopontin was noted in almost all cases, including papillary renal cell adenomas. In the only negative sample of papillary renal cell carcinoma, which was diagnosed in 1989, the positive control, i.e. staining of distal tubules and calcifications, was very weak, probably due to poor quality of paraffin used in the past. Therefore, the lack of osteopontin expression in this particular case could possibly present false negative staining result. In our papillary carcinoma sample, type 2 morphology of tumors was associated with poor prognostic variables, as has been recently proposed. 7 However, it does not seem to be related to the expression of osteopontin, which was also present in type 1 carcinomas, as well as in renal cell adenomas.
It is well known that osteopontin promoter is responsive to many agents, including cytokines, growth factors and hormones. 6, 23 Many of the factors that enhance osteopontin expression have in common the fact that they increase Ras expression, and activation of Ras is known to stimulate osteopontin expression.
14 Increased expression of osteopontin itself can lead, via osteopontin-mediated signaling, to upregulation of other genes important to tumor progression and metastasis. 23 Experimental results suggest that the role of osteopontin in tumor development is complex, and may be affected by a variety of parameters, including tumor type and growth factor milieu, which may reflect a role of the tumor microenvironment in determining the effects of osteopontin. 23 In papillary renal cell tumors, overexpression of a candidate gene associated with the polysomy of chromosome 7, could be the c-met proto-oncogene, 17 which encodes for the receptor for hepatocyte growth factor (HGF), a multifunctional cytokine stimulating cell proliferation and motility. Recently, osteopontin has been identified as a protein whose expression was upregulated upon HGF stimulation, and it was proposed that, together with other molecules, osteopontin might contribute to HGF-induced tumor growth. 3 Therefore, it is possible that constitutive expression of osteopontin in papillary renal cell carcinoma could be related to mutation or overexpression of c-met protein.
In conclusion, in the present study we have shown for the first time the upregulation of CD44 molecule and osteopontin in a series of papillary renal cell carcinoma. Although both adhesive molecules were presented in higher percentage of tumors compared to clear cell type, they do not seem to have prognostic importance as described for the most common type of renal cell carcinoma. The results support different biology and different factors involved in progression of these two types of renal cell carcinoma. However, our finding of constitutive expression of osteopontin in papillary renal cell carcinoma could contribute to the differential diagnosis of difficult cases.
